Welcome to our dedicated page for Dogwood Therapeutics news (Ticker: DWTX), a resource for investors and traders seeking the latest updates and insights on Dogwood Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dogwood Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dogwood Therapeutics's position in the market.
Dogwood Therapeutics (DWTX) announced Q3 2024 financial results following its formation in October through the combination of Virios Therapeutics and Pharmagesic Holdings. The company secured $19.5M in debt financing, with $16.5M funded and $3.0M expected in Q1 2025. Their pipeline includes Halneuron® for chemotherapy-induced neuropathic pain (Phase 2b), IMC-1 for fibromyalgia (Phase 3-ready), and IMC-2 for Long-COVID (Phase 2a). Q3 net loss was $2.3M ($2.05 per share) compared to $1.2M ($1.62 per share) in Q3 2023. Top-line results from the Long-COVID study are expected mid-November 2024.
Dogwood Therapeutics (Nasdaq: DWTX), a clinical-stage biopharmaceutical company formerly known as Virios Therapeutics, has announced it will release its Q3 2024 financial results on Thursday, November 7, 2024, before market open. The company will host a webcast and conference call at 8:30 a.m. ET on the same day, featuring management discussion of results and a corporate update. Investors can access the live call by dialing 888-506-0062 (domestic) or 973-528-0011 (international) using access code 838895, or view the webcast through the company's website under the Investors section.
Dogwood Therapeutics (DWTX) has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market. The company, previously known as Virios Therapeutics, reported two significant developments: upcoming top-line results from the Bateman Horne Center's phase 2a study of IMC-2 for Long-COVID treatment, expected in mid-November 2024, and ongoing integration efforts following their recent acquisition of Pharmagesic Holdings in early October 2024.
FAQ
What is the current stock price of Dogwood Therapeutics (DWTX)?
What is the market cap of Dogwood Therapeutics (DWTX)?
